Mizuho Securities analyst Vamil Divan maintained a Buy rating on Alkermes (NASDAQ:ALKS) on Wednesday, setting a price target of $36, which is approximately 14.25% above the present share price of $31.51.
Divan expects Alkermes to post earnings per share (EPS) of $0.01 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Hold rating of shares in Alkermes, with an average price target of $31.
The analysts price targets range from a high of $36 to a low of $25.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $303.72 million and a net profit of $4.42 million. The company's market cap is $5.08 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.6% and a 48.29% success rate.
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.